Hepatitis D treatment combo granted new designations in US, EU
Tobevibart and elebsiran, an experimental treatment combination that Vir Biotechnology is developing for chronic hepatitis D, has been awarded both breakthrough therapy designation…
Marisa Wexler, MS, Senior Science Writer — 
Articles by Marisa Wexler
Committee recommends seladelpar approval in EU for treating PBC
A branch of the European Medicines Agency (EMA) has recommended that Gilead Sciences’ oral therapy seladelpar be approved in the European Union as a…
Cholestasis common in COVID 19-linked ARDS, study shows
Cholestasis is a common complication among critically ill people with COVID 19-associated acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure, a…
Vascular health checks, kidney tests urged for Alagille patients: Review
Kidney and blood vessel problems are common in people with Alagille syndrome, and while these often cause few to no symptoms, they can be…
PBC treatment Livdelzi shows benefits for 2.5 years in Phase 3 trial
After 2.5 years of Livdelzi (seladelpar) treatment, more than 4 in 5 adults with primary biliary cholangitis (PBC) saw meaningful reductions in liver…
Bylvay eases itch over long term in PFIC, Alagille syndrome patients
Nearly 1.5 years of treatment with Bylvay (odevixibat) effectively reduces itching and liver damage markers, and improves growth and sleep in people with…
Iqirvo to treat PBC approved for public funding in England and Wales
England’s National Institute for Health and Care Excellence (NICE) has recommended that Iqirvo (elafibranor) be covered by the country’s National Health Service (NHS)…
PFIC caused by USP53 usually mild form of liver disease: Study
Progressive familial intrahepatic cholestasis (PFIC) caused by mutations in the USP53 gene results in a fairly mild form of the disease, with most of…
Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD
Sagimet Biosciences is planning the launch of two Phase 3 clinical trials to test its oral therapy candidate denifanstat in people with fatty…
Protein in blood may be liver scarring marker in biliary atresia
Higher levels of a protein called amyloid precursor protein (APP) in the blood may be a marker of fibrosis, or liver scarring, in biliary…